The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1655
ISSUE1655
July 25, 2022
Drugs for Treatment and Prevention of Venous Thromboembolism
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Treatment and Prevention of Venous Thromboembolism
July 25, 2022 (Issue: 1655)
Anticoagulants are the drugs of choice for treatment
and prevention of deep venous thrombosis (DVT) and
pulmonary embolism (PE), collectively referred to as
venous thromboembolism (VTE). US guidelines for
treatment of VTE were updated in 2020 and...more
- TL Ortel et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4:4693.
- SM Stevens et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 2021; 160:e545.
- CD Jackson et al. Antithrombotic therapy for venous thromboembolism. JAMA 2022; 327:2141.
- Y Falck-Ytter et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 Suppl):e278S.
- MK Gould et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141(2 Suppl):e227S.
- DR Anderson et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv 2019; 3:3898.
- HJ Schünemann et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and non-hospitalized medical patients. Blood Adv 2018; 2:3198.
- C Wall et al. Catheter-related thrombosis: a practical approach. J Intensive Care Soc 2016; 17:160.
- SA Smith et al. How it all starts: initiation of the clotting cascade. Crit Rev Biochem Mol Biol 2015; 50:326.
- New oral anticoagulants for acute venous thromboembolism. Med Lett Drugs Ther 2014; 56:3.
- KA Martin et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC subcommittee on control of anticoagulation. J Thromb Haemost 2021; 19:1874.
- S Schulman et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342.
- S Schulman et al. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med 2013; 368:709.
- FDA Drug Safety Communication: FDA study of medicare patients finds risks lower for stroke and death but higher for gastrointestinal bleeding with Pradaxa (dabigatran) compared to warfarin. May 13, 2014. Available at: https://bit.ly/3ydIXAG. Accessed July 7, 2022.
- EINSTEIN Investigators et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363:2499.
- EINSTEIN-PE Investigators et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366:1287.
- Rivaroxaban (Xarelto) – a new oral anticoagulant. Med Lett Drugs Ther 2011; 53:65.
- G Agnelli et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369:799.
- MR Lassen et al. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet 2010; 375:807.
- MR Lassen et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363:2487.
- Hokusai-VTE Investigators et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369:1406.
- N van Es et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124:1968.
- N Kang and DM Sobieraj. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thromb Res 2014; 133:1145.
- GK Dawwas et al. Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data. Ann Intern Med 2022; 175:20.
- M Giustozzi et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis. Thromb Haemost 2020; 120:1128.
- G Agnelli et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382:1599.
- K Uchino and AV Hernandez. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172:397.
- AYY Lee. Anticoagulant therapy for venous thromboembolism in cancer. N Engl J Med 2020; 382:1650.
- CYS Cheung et al. Direct oral anticoagulant use in chronic kidney disease and dialysis patients with venous thromboembolism: a systematic review of thrombosis and bleeding outcomes. Ann Pharmacother 2021: 55:711.
- J Ordi-Ros et al. Rivaroxaban versus vitamin K antagonist in antiphospholipid syndrome: a randomized noninferiority trial. Ann Intern Med 2019; 171:685.
- SC Woller et al. Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial. Blood Adv 2022; 6:1661.
- A Dhar et al. Anticoagulation in chronic liver disease. J Hepatol 2017; 66:1313.
- L Vasanthamohan et al. Reduced-dose direct oral anticoagu-lants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost 2018; 16:1288.
- C Becattini et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366:1959.
- TA Brighton et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367:1979.
- G Agnelli et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368:699.
- JI Weitz et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017; 376:1211.
- Which oral anticoagulant for atrial fibrillation? Med Lett Drugs Ther 2016; 58:45.
- MR Lassen et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358:2776.
- MR Lassen et al. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 2010; 363:2487.
- T Haykal et al. Thromboprophylaxis for orthopedic surgery; an updated meta-analysis. Thromb Res 2021; 199:43.
- BT Venker et al. Safety and efficacy of new anticoagulants for the prevention of venous thromboembolism after hip and knee arthroplasty: a meta-analysis. J Arthroplasty 2017; 32:645.
- DR Anderson et al. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. N Engl J Med 2018; 378:699.
- I Neumann et al. DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. Blood Adv 2020; 4:1512.
- S Kaatz et al. Reversing factor Xa inhibitors – clinical utility of andexanet alfa. J Blood Med 2017; 8:141.
- E Carpenter et al. Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation. Ther Adv Drug Saf 2019 Nov 26 (epub).
- S Christos and R Naples. Anticoagulation reversal and treatment strategies in major bleeding: update 2016. West J Emerg Med 2016; 17:264.
- Kcentra: a 4-factor prothrombin complex concentrate for reversal of warfarin anticoagulation. Med Lett Drugs Ther 2013; 55:53.
- Idarucizumab (Praxbind) – an antidote for dabigatran. Med Lett Drugs Ther 2015; 57:157.
- CV Pollack Jr. et al. Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med 2017; 377:431.
- Andexxa – an antidote for apixaban and rivaroxaban. Med Lett Drugs Ther 2018; 60:99.
- SJ Connolly et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med 2019; 380:1326.
- SJ Connolly et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375:1131.
- GF Tomaselli et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2020; 76:594.
- SM Bates et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism in the context of pregnancy. Blood Adv 2018; 2:3317.
- S Nopp et al. Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thromb Haemost 2020; 4:1178.
- COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Available at: https://bit.ly/3w2faYJ. Accessed July 7, 2022.
- LK Moores et al. Thromboprophylaxis in patients with COVID-19: a brief update to the CHEST guideline and expert panel report. Chest 2022 Feb 12 (epub).
- A Cuker et al. American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Adv 2022 May 3 (epub).
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Treatment and Prevention of Venous Thromboembolism
Article code: 1655a
Article code: 1655a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.